Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh […]
Targeting the Root Causes of Aging Demonstrates Powerful Anti-Cancer Activity Across Multiple Tumor Models Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease™, today announced the publication of its international patent application PCT/WO2025184665[1], entitled “Senescence Vaccine.” The application describes Immorta Bio's proprietary approach to
(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva's strong biosimilars portfolio, in line with Teva's Pivot to Growth
(NASDAQ:NNOX), Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's fourth European distribution agreement following recent collaborations in Greece, Romania and Czech Republic PETACH TIKVA, ISRAEL – November 25, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the
National plaintiffs' law firm Berger Montague PCannounces a class action lawsuit against James Hardie Industries plc (NYSE: JHX) (“James Hardie” or the “Company”) on behalf of investors who purchased James Hardie common stock and American Depositary Shares during the period ofMay 20, 2025 through August 18, 2025 (the “Class Period”). https://mma.prnewswire.com/media/232479/berger_montague.jpg Investor Deadline: Investors who
Strategic acquisition will accelerate growth by embedding advanced multilingual AI across the Gloo platform Gloo (Nasdaq: GLOO), a technology platform serving the faith and flourishing ecosystem, announced it has acquired XRI Global, an AI company pioneering voice AI and multilingual technologies designed to engage people across thousands of languages. https://mma.prnewswire.com/media/2831576/XRI_Press_Release__1.jpg XRI's capabilities allow Gloo to
Teva receives European Commission approvals for PONLIMSI(R) (denosumab) Biosimilar to Prolia(R) and DEGEVMA(R) (denosumab) Biosimilar to Xgeva(R) GlobeNewswire November 25, 2025 Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments
Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System GlobeNewswire November 25, 2025 Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's fourth European distribution agreement following recent collaborations in Greece, Romania and Czech Republic PETACH
(Norwegian OTC:GOL),(NASDAQ:GLNG),(Oslo Bors:GLNG), Golar LNG Limited (“Golar”) is pleased to announce that it has successfully closed and drawn a new $1.2 billion asset backed debt facility agreement with a consortium of banks including ABN AMRO, Citibank, DNB, Goldman Sachs and Standard Chartered Bank for the refinancing of FLNG Gimi. The new $1.2bn bank facility replaces
— Building on a successful collaboration over the past four years,Globant will deliver a broad portfolio of IT solutions, software and digital platform development services to FIFA — The digital consultant and software development provider signs on as a Tournament Supporter for North America and Europe for theFIFA World Cup 2026™ and the FIFA Women's